Evaluating an 'incident control' approach to non-communicable disease.

Evaluation Incident control Inequalities Lung cancer Non-communicable diseases Survival

Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 30 09 2020
revised: 19 03 2021
accepted: 30 04 2021
pubmed: 11 7 2021
medline: 22 9 2021
entrez: 10 7 2021
Statut: ppublish

Résumé

This article evaluates the application of 'incident control' methodology usually applied in communicable disease control to an 'incident' of unexplained deaths, specifically to resolve a significant difference in 1-year survival after a lung cancer diagnosis observed between two Clinical Commissioning Groups and the England national average, 2011-14. The purpose of the evaluation was to assess whether a formalised incident control approach is feasible and effective in improving outcomes for non-communicable diseases. Descriptive, qualitative, process evaluation. There were two components to the evaluation: a document review against identified phases of a non-communicable disease incident control framework and a qualitative analysis of semi-structured interviews with stakeholders who had been involved in implementation. The findings indicate feasibility of the incident control model, with some limitations. Identified strengths of the model included the articulation of a clear case and incident definition. The structure and stepped phased approach facilitated partner engagement, robust data analysis, action planning and communication strategies. Delays in data publication and the lack of comparable data across different non-communicable diseases present challenges in timely response and prioritisation of 'incidents'. The evaluation indicates value in applying defined incident control methodology to management of non-communicable diseases, especially where there is identification of a potential outlier or a measurable variation, i.e. there is a definable 'incident' and 'case'.

Identifiants

pubmed: 34245950
pii: S0033-3506(21)00177-3
doi: 10.1016/j.puhe.2021.04.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Subventions

Organisme : Medical Research Council
ID : MR/P008348/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Royal Society for Public Health. All rights reserved.

Auteurs

S M Horsley (SM)

Public Health England, Midlands Centre, UK. Electronic address: Siobhan.Horsley@phe.gov.uk.

J R Morling (JR)

Public Health England, Midlands Centre, UK; Division of Epidemiology and Public Health, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, NG7 2UH, UK.

F M Khaw (FM)

Public Health England, Midlands Centre, UK.

M Day (M)

Public Health England, Midlands Centre, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH